IGI Logo

Zydus Lifesciences is currently trading at Rs. 376.20, up by 3.00 points or 0.80% from its previous closing of Rs. 373.20 on the BSE.

The scrip opened at Rs. 375.00 and has touched a high and low of Rs. 376.20 and Rs. 373.00 respectively. So far 1701 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 673.70 on 12-May-2021 and a 52 week low of Rs. 331.00 on 07-Mar-2022.

Last one week high and low of the scrip stood at Rs. 379.00 and Rs. 362.95 respectively. The current market cap of the company is Rs. 38206.07 crore.

The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 15.66% and 9.46% respectively.

Zydus Lifesciences has received Prior Approval Supplement (PAS) approval from the USFDA to market Mycophenolate Mofetil for Injection USP, 500 mg/vial (US RLD: CellCept injection). The injection will be manufactured at the group’s injectables manufacturing facility at Jarod near Vadodara in Gujarat.

The Prior Approval Supplement (PAS) was for a site transfer into the Jarod site. This site was recently inspected by the USFDA. Earlier, in September 2017, the group was granted approval to market Mycophenolate Mofetil for Injection in the strength of 500 mg/vial. Mycophenolate Mofetil is indicated for use in combination with other drugs i.e., cyclosporine and corticosteroids for the prophylaxis of organ rejection in patients receiving renal, hepatic or cardiac transplants. The group now has 330 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.